• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs.

作者信息

Overbeek J K, Ter Heine R, Verheul H M W, Chatelut E, Rudek M A, Gurney H, Plummer R, Gilbert D C, Buclin T, Burger D M, Bloemendal H J, van Erp N P

机构信息

Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands.

Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen; Department of Medical Oncology, Erasmus University MC Cancer Institute, Rotterdam, Netherlands.

出版信息

ESMO Open. 2023 Feb;8(1):100749. doi: 10.1016/j.esmoop.2022.100749. Epub 2023 Jan 3.

DOI:10.1016/j.esmoop.2022.100749
PMID:36603522
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9813708/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8730/9813708/a5055dceb3d6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8730/9813708/a5055dceb3d6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8730/9813708/a5055dceb3d6/gr1.jpg

相似文献

1
Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs.标签外用药，但靶向明确：实施抗癌药物替代给药方案所需的证据
ESMO Open. 2023 Feb;8(1):100749. doi: 10.1016/j.esmoop.2022.100749. Epub 2023 Jan 3.
2
Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.癌症药物的可及性：许多基于证据的治疗方法都是未被批准的适应证用药，未被药品福利计划所覆盖。
Intern Med J. 2012 Nov;42(11):1224-9. doi: 10.1111/j.1445-5994.2012.02751.x.
3
Off-label use of anti-cancer drugs in India: to be or not to be!印度抗癌药物的非标签使用：何去何从！
J Cancer Res Ther. 2011 Jan-Mar;7(1):35-9. doi: 10.4103/0973-1482.80455.
4
Reflections about off-label use of anticancer drugs.关于抗癌药物的超说明书用药的思考。
Ther Drug Monit. 2012 Oct;34(5):604. doi: 10.1097/FTD.0b013e318268478d.
5
Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study.瑞士东部抗癌药物的非标签使用：一项基于人群的前瞻性队列研究。
Eur J Clin Pharmacol. 2014 Jun;70(6):719-25. doi: 10.1007/s00228-014-1662-5. Epub 2014 Mar 11.
6
Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center.在一家大型儿科癌症中心的标签外处方靶向抗癌治疗。
Cancer Med. 2020 Sep;9(18):6658-6666. doi: 10.1002/cam4.3349. Epub 2020 Aug 4.
7
A uniform procedure for reimbursing the off-label use of antineoplastic drugs according to the value-for-money approach.一种根据性价比方法对抗肿瘤药物的超说明书用药进行报销的统一程序。
J Chemother. 2011 Apr;23(2):67-70. doi: 10.1179/joc.2011.23.2.67.
8
Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.支持试验证据与癌症药物标签外使用报销的关联。
JAMA Netw Open. 2021 Mar 1;4(3):e210380. doi: 10.1001/jamanetworkopen.2021.0380.
9
[Anticancer drugs off label used of: what do the experts think about?].[抗癌药物的超说明书使用：专家们怎么看？]
Bull Cancer. 2004 Oct;91(10):769-77.
10
Off-label drug use in oncology: a systematic review of literature.肿瘤学中的药物非标签使用：文献系统综述
J Clin Pharm Ther. 2017 Jun;42(3):251-258. doi: 10.1111/jcpt.12507. Epub 2017 Feb 5.

引用本文的文献

1
Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology.证据的总体情况：优化肿瘤学中的剂量选择策略
J Clin Oncol. 2025 Jul 24:JCO2500488. doi: 10.1200/JCO-25-00488.
2
Model-informed development of a cost-saving dosing regimen for enfortumab vedotin.基于模型的安维汀（enfortumab vedotin）节约成本给药方案的开发。
Cancer Chemother Pharmacol. 2025 Feb 25;95(1):36. doi: 10.1007/s00280-025-04764-x.
3
High-dose short-term osimertinib treatment is effective in patient-derived metastatic colorectal cancer organoids.
大剂量短期奥希替尼治疗对患者来源的转移性结直肠癌类器官有效。
BJC Rep. 2024 Apr 3;2(1):29. doi: 10.1038/s44276-024-00042-0.
4
Population Pharmacokinetics in Oncology and Its Clinical Applications.肿瘤学中的群体药代动力学及其临床应用。
Pharmaceutics. 2024 May 25;16(6):711. doi: 10.3390/pharmaceutics16060711.
5
Optimising oncology drug expenditure in Ireland.优化爱尔兰的肿瘤药物支出。
Ir J Med Sci. 2024 Aug;193(4):1735-1747. doi: 10.1007/s11845-024-03672-y. Epub 2024 Apr 3.
6
Integrating treatment cost reduction strategies and biomarker research to reduce costs and personalize expensive treatments: an example of a self-funding trial in non-small cell lung cancer.整合治疗成本降低策略与生物标志物研究以降低成本并使昂贵治疗个性化：非小细胞肺癌自筹资金试验的一个实例。
Front Pharmacol. 2023 Nov 28;14:1274532. doi: 10.3389/fphar.2023.1274532. eCollection 2023.
7
Pharmacokinetic Boosting of Kinase Inhibitors.激酶抑制剂的药代动力学增强
Pharmaceutics. 2023 Apr 5;15(4):1149. doi: 10.3390/pharmaceutics15041149.
8
From Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure.从肿瘤学中的个性化医疗到精准医疗：一种基于模型的给药方法以优化伊马替尼目标暴露的实现。
Pharmaceutics. 2023 Mar 28;15(4):1081. doi: 10.3390/pharmaceutics15041081.